No. of Recommendations: 1
Speaking of German multinationals nobody wants touch with a ten-foot pole, Bayer might be worth a look. The RoundUp / glyphosate litigation seems likely to drag on somewhere between "a while yet" and "forever," but if it's closer to the former than the latter, the current price might be pretty cheap. Since there's probably no informational advantage to be had there, it might be better to think of it in terms of an asymmetric bet rather than a true workout. Provided Bayer remains a going concern, there is some price at which the risk is very attractive.
